Fosun Pharma Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
40,557
- Stock Symbol
-
600196
- Investments
-
96
- Share Price
-
$3.26
- (As of Friday Closing)
Fosun Pharma General Information
Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
Contact Information
Website
www.fosunpharma.comCorporate Office
- Number 1289 Yishan Road
- Building A, Fosun Technology Park
- Shanghai, 200233
- China
Corporate Office
- Number 1289 Yishan Road
- Building A, Fosun Technology Park
- Shanghai, 200233
- China
Fosun Pharma Stock Performance
As of 09-May-2025, Fosun Pharma’s stock price is $3.26. Its current market cap is $7.88B with 2.67B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.26 | $3.30 | $2.97 - $4.34 | $7.88B | 2.67B | 15.1M | $0.15 |
Fosun Pharma Financials Summary
As of 31-Mar-2025, Fosun Pharma has a trailing 12-month revenue of $5.6B.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 12,787,090 | 12,642,811 | 12,454,675 | 15,751,351 |
| Revenue | 5,597,414 | 5,723,284 | 5,851,624 | 6,526,288 |
| EBITDA | 771,918 | 1,146,899 | 1,016,404 | 1,127,243 |
| Net Income | 405,947 | 386,022 | 337,287 | 553,981 |
| Total Assets | 16,243,631 | 16,090,268 | 16,007,336 | 15,532,577 |
| Total Debt | 4,990,330 | 4,953,097 | 4,952,962 | 4,384,174 |
Fosun Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Fosun Pharma Comparisons
Industry
Financing
Details
Fosun Pharma Competitors (3)
One of Fosun Pharma’s 3 competitors is Cipla, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cipla | Corporation | Mumbai, India | ||||
| Roche | Corporation | Basel, Switzerland | ||||
| Dr. Reddy's Laboratories | Corporation | Hyderabad, India |
Fosun Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Fosun Pharma Investments & Acquisitions (96)
Fosun Pharma’s most recent deal was a Later Stage VC with Fosun Health Insurance for . The deal was made on 01-Apr-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Fosun Health Insurance | 01-Apr-2025 | Later Stage VC | Insurance Brokers | ||
| Zhuoerhui Comprehensive Clinic | 19-Feb-2025 | Corporate | Clinics/Outpatient Services | ||
| Shanghai Helius | 22-Jan-2025 | Secondary Transaction - Private | Drug Discovery | ||
| Fosun Antejin | 11-Oct-2024 | Later Stage VC | Biotechnology | ||
| Fosun Kite Biotechnology | 13-Sep-2024 | Merger/Acquisition | Drug Discovery |
Fosun Pharma ESG
Risk Overview
Risk Rating
Updated August, 12, 2024
29.99 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
Fosun Pharma Exits (22)
Fosun Pharma’s most recent exit was on 26-Mar-2021 from Gyroscope. The exit was categorized as with 6 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Gyroscope | 26-Mar-2021 | Completed |
|
||
| Hinova Pharmaceuticals | 24-Aug-2020 | Completed |
|
||
| BioNTech | 17-Mar-2020 | Completed |
|
||
| Hinova Pharmaceuticals | 26-Jul-2019 | Completed |
|
||
| EOS Imaging | 10-Dec-2018 | PIPE | Completed |
Fosun Pharma Affiliates
Subsidiaries (19)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| XingMeiShengWu | Tianjin, China | 2020 | |
| Fosun Health Capital | Shanghai, China | 2019 | |
| Fosun Kite Biotechnology | Shanghai, China | 2017 | |
| Fosun Aitrox | Shanghai, China | 2017 | |
| Fosun Antejin | Chengdu, China | 2012 |
Fosun Pharma FAQs
-
When was Fosun Pharma founded?
Fosun Pharma was founded in 1994.
-
Where is Fosun Pharma headquartered?
Fosun Pharma is headquartered in Shanghai, China.
-
What is the size of Fosun Pharma?
Fosun Pharma has 40,557 total employees.
-
What industry is Fosun Pharma in?
Fosun Pharma’s primary industry is Drug Delivery.
-
Is Fosun Pharma a private or public company?
Fosun Pharma is a Public company.
-
What is Fosun Pharma’s stock symbol?
The ticker symbol for Fosun Pharma is 600196.
-
What is the current stock price of Fosun Pharma?
As of 09-May-2025 the stock price of Fosun Pharma is $3.26.
-
What is the current market cap of Fosun Pharma?
The current market capitalization of Fosun Pharma is $7.88B.
-
What is Fosun Pharma’s current revenue?
The trailing twelve month revenue for Fosun Pharma is $5.6B.
-
Who are Fosun Pharma’s competitors?
Cipla, Roche, and Dr. Reddy's Laboratories are competitors of Fosun Pharma.
-
What is Fosun Pharma’s annual earnings per share (EPS)?
Fosun Pharma’s EPS for 12 months was $0.15.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
